肿瘤相关性高血糖管理指南(2021年版)

2021-07-30 中国抗癌协会肿瘤内分泌专业委员会 中国癌症杂志

恶性肿瘤逐渐成为中国最常见的威胁生命的慢性非传染性疾病,近年来研究发现,恶性肿瘤与高血糖及糖尿病关系密切。一方面,高血糖和糖尿病可以增加多种恶性肿瘤的发病率,且与其不良预后密切相关。

中文标题:

肿瘤相关性高血糖管理指南(2021年版)

发布日期:

2021-07-30

简要介绍:

恶性肿瘤逐渐成为中国最常见的威胁生命的慢性非传染性疾病,近年来研究发现,恶性肿瘤与高血糖及糖尿病关系密切。一方面,高血糖和糖尿病可以增加多种恶性肿瘤的发病率,且与其不良预后密切相关。另一方面,部分肿瘤本身可导致高血糖和糖尿病。此外,在治疗恶性肿瘤的过程中也会出现高血糖和糖尿病。以上统称为肿瘤相关性高血糖,但目前尚无相关的指南可用于指导临床诊治和管理。中国抗癌协会肿瘤内分泌专业委员会和重庆市中西医结合学会肿瘤内分泌分会组织专家对肿瘤相关性高血糖的研究进展进行归纳总结,旨在及时传递重要信息,指导临床实践。本指南主要涵盖肿瘤相关性高血糖的概述、临床诊治管理和长期随访管理,将有助于临床医师对肿瘤相关性高血糖患者进行规范化管理,改善中国肿瘤相关性高血糖患者的临床结局。

相关资料下载:
[AttachmentFileName(sort=1, fileName=肿瘤相关性高血糖管理指南(2021年版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=061231c0021901ff, title=肿瘤相关性高血糖管理指南(2021年版), enTitle=, guiderFrom=中国癌症杂志, authorId=0, author=, summary=恶性肿瘤逐渐成为中国最常见的威胁生命的慢性非传染性疾病,近年来研究发现,恶性肿瘤与高血糖及糖尿病关系密切。一方面,高血糖和糖尿病可以增加多种恶性肿瘤的发病率,且与其不良预后密切相关。, cover=https://img.medsci.cn/2021920/1632109506940_5579292.jpg, journalId=0, articlesId=null, associationId=1980, associationName=中国抗癌协会肿瘤内分泌专业委员会, associationIntro=中国抗癌协会肿瘤内分泌专业委员会, copyright=0, guiderPublishedTime=Fri Jul 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">恶性肿瘤逐渐成为中国最常见的威胁生命的慢性非传染性疾病,近年来研究发现,恶性肿瘤与高血糖及糖尿病</span><span style="color: #373737;">关系密切。一方面,高血糖和糖尿病可以增加多种恶性肿瘤的发病率,且与其不良预后密切相关。另一方面,部分肿瘤本</span><span style="color: #373737;">身可导致高血糖和糖尿病。此外,在治疗恶性肿瘤的过程中也会出现高血糖和糖尿病。以上统称为肿瘤相关性高血糖,但</span><span style="color: #373737;">目前尚无相关的指南可用于指导临床诊治和管理。中国抗癌协会肿瘤内分泌专业委员会和重庆市中西医结合学会肿瘤内分</span><span style="color: #373737;">泌分会组织专家对肿瘤相关性高血糖的研究进展进行归纳总结,旨在及时传递重要信息,指导临床实践。本指南主要涵盖</span><span style="color: #373737;">肿瘤相关性高血糖的概述、临床诊治管理和长期随访管理,将有助于临床医师对肿瘤相关性高血糖患者进行规范化管理,</span><span style="color: #373737;">改善中国肿瘤相关性高血糖患者的临床结局。</span></p>, tagList=[TagDto(tagId=115009, tagName=肿瘤相关性高血糖)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2664, guiderKeyword=高血糖, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3338, appHits=120, showAppHits=0, pcHits=453, showPcHits=3217, likes=1, shares=13, comments=6, approvalStatus=1, publishedTime=Mon Sep 20 11:47:28 CST 2021, publishedTimeString=2021-07-30, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Sep 20 11:47:01 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 13:01:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=肿瘤相关性高血糖管理指南(2021年版).pdf)])
肿瘤相关性高血糖管理指南(2021年版).pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1068582, encodeId=c7b2106858298, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Tue Nov 09 13:37:04 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056635, encodeId=8767105663578, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0745617115, createdName=ms3000001484629677, createdTime=Thu Sep 30 20:38:55 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053812, encodeId=0ee510538120a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd1c2561472, createdName=125638e2m96暂无昵称, createdTime=Wed Sep 22 15:30:55 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053245, encodeId=8442105324586, content=非常实用!紧密结合临床!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee641592989, createdName=guoguolijuan, createdTime=Mon Sep 20 12:30:46 CST 2021, time=2021-09-20, status=1, ipAttribution=)]
    2021-11-09 146475c0m26(暂无昵称)

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1068582, encodeId=c7b2106858298, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Tue Nov 09 13:37:04 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056635, encodeId=8767105663578, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0745617115, createdName=ms3000001484629677, createdTime=Thu Sep 30 20:38:55 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053812, encodeId=0ee510538120a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd1c2561472, createdName=125638e2m96暂无昵称, createdTime=Wed Sep 22 15:30:55 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053245, encodeId=8442105324586, content=非常实用!紧密结合临床!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee641592989, createdName=guoguolijuan, createdTime=Mon Sep 20 12:30:46 CST 2021, time=2021-09-20, status=1, ipAttribution=)]
    2021-09-30 ms3000001484629677

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1068582, encodeId=c7b2106858298, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Tue Nov 09 13:37:04 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056635, encodeId=8767105663578, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0745617115, createdName=ms3000001484629677, createdTime=Thu Sep 30 20:38:55 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053812, encodeId=0ee510538120a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd1c2561472, createdName=125638e2m96暂无昵称, createdTime=Wed Sep 22 15:30:55 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053245, encodeId=8442105324586, content=非常实用!紧密结合临床!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee641592989, createdName=guoguolijuan, createdTime=Mon Sep 20 12:30:46 CST 2021, time=2021-09-20, status=1, ipAttribution=)]
    2021-09-22 125638e2m96暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1068582, encodeId=c7b2106858298, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Tue Nov 09 13:37:04 CST 2021, time=2021-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056635, encodeId=8767105663578, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0745617115, createdName=ms3000001484629677, createdTime=Thu Sep 30 20:38:55 CST 2021, time=2021-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053812, encodeId=0ee510538120a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd1c2561472, createdName=125638e2m96暂无昵称, createdTime=Wed Sep 22 15:30:55 CST 2021, time=2021-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1053245, encodeId=8442105324586, content=非常实用!紧密结合临床!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee641592989, createdName=guoguolijuan, createdTime=Mon Sep 20 12:30:46 CST 2021, time=2021-09-20, status=1, ipAttribution=)]
    2021-09-20 guoguolijuan

    非常实用!紧密结合临床!

    0

拓展阅读

2013中国成人住院患者高血糖管理目标专家共识

中华医学会内分泌学分会(CSE,Chinese Society of Endocrinology) · 2013-03-25

2015 ADA/EASD立场声明-2型糖尿病患者的高血糖管理:以患者为中心的治疗

美国糖尿病学会(ADA,American Diabetes Association) · 2014-12-20

中国高血糖危象诊断与治疗指南2013

中华医学会糖尿病学分会(CDS,Chinese Diabetes Society) · 2016-04-27

2018 ADA/EASD共识:2型糖尿病患者高血糖的管理

美国糖尿病学会(ADA,American Diabetes Association) · 2018-10-04

2019 ADA/EASD共识:2型糖尿病患者高血糖的管理(更新版)

美国糖尿病学会(ADA,American Diabetes Association) · 2019-12-19